搜索结果
靶点ID:TCMBANKGE010186
靶点别名:HAP; MCOPS12; NR1B2; RARbeta1; RRB2
靶点描述:retinoic acid receptor beta
染色体:3
染色体位置:3p24.2
靶点类型:protein-coding
HERB_ID:-
HGNC_Link:9865
OMIM_Link:180220
Ensembl_Link:ENSG00000077092
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN003665 | evoden | C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O | |||
| TCMBANKIN014683 | Tobacco ene | C9H6Cl6O3S | C1C2C(COS(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl | ||
| TCMBANKIN033702 | citric acid | InChI=1/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12; NCGC00090954-02; NCGC00090954-01; HSDB 911; CIT; Citric acid (8CI); BRN 0782061; NCIStruc2_000099; 27109_RIEDEL; AIDS-017733; 1,2,3-PROPANETRICARBOXYLIC ACID,2-HYDROXY (CITRIC ACID); citr; 27488_FLUKA; FEMA No. 2306; E 330; 27485_FLUKA; 27487_FLUKA; 77-92-9; C2404_SIGMA; 2-Hydroxytricarballylic acid; NCIOpen2_004502; F 0001 (polycarboxylic acid); EPA Pesticide Chemical Code 021801; AI3-06286; 245654-34-6; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-; Citretten; Kyselina citronova; 2-hydroxypropane-1,2,3-tricarboxylic acid; Anhydrous citric acid; Citrate standard for IC; C83155_SIAL; LS-2418; WLN: QV1XQVQ1VQ; 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI); NSC30279; .beta.-Hydroxytricarballylic acid; NSC 626579; FLC; NCI60_022579; LS-3185; 2-hydroxy-1,2,3-propanetricarboxylic acid; Caswell No. 221C; EINECS 201-069-1; 43136-35-2; 251275_SIAL; 38730_FLUKA; C4540_SIGMA; FEMA Number 2306; 4-03-00-01272 (Beilstein Handbook Reference); 3-Carboxy-3-hydroxypentane-1,5-dioic acid; Citric acid anhydrous (JAN); C00158; 12262-73-6; 240621_ALDRICH; AIDS017733; MLS001066346; Kyselina 2-hydroxy-1,2,3-propantrikarbonova [Czech]; 2-Hydroxypropanetricarboxylic acid; CCRIS 3292; KBio3_002740; NSC626579; D00037; SBB008922; Kyselina citronova [Czech]; Aciletten; NSC 30279; Anhydrous citric acid (JP15); 46933_SUPELCO; NCIOpen2_004062; Citric acid solution; CHEBI:30769; Citro; BSPBio_003240; NCIStruc1_000057; Uro-trainer; Citric acid, anhydrous (USP); W230618_ALDRICH; Citric acid [USAN:JAN]; H3cit; Chemfill; Hydrocerol A; Suby G; Oprea1_502996; Citric acid, anhydrous; SMR000471840; Citric acid anhydrous; Spectrum3_001850 | C6H8O7 | 192.12 | C(C(=O)O)C(CC(=O)O)(C(=O)O)O |
| TCMBANKIN039211 | Haginin E | 240.25 g/mol | |||
| TCMBANKIN058519 | (-)-epigallocatechin-3-gallate; (-)-epigallocatechin 3-o-gallate;epigallocatechin gallate; galloyl-l-epigallocatechol; epigallocatechin 3-gallate; (-)-epigallocatechin gallate; | KBio2_000796; SpecPlus_000277; 50299_FLUKA; Spectrum3_000244; KBioGR_002002; 3,4,5-trihydroxybenzoic acid [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] ester; MLS000758300; DivK1c_006373; (−)-Epigallocatechin gallate; EGCG; SPBio_000035; (−)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; KBioSS_000796; Epigallocatechin gallate; Spectrum4_001541; (-)-epigallocatechin 3-gallate; Tea catechin; AIDS000674; KBio2_005932; 3,4,5-trihydroxybenzoic acid [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3-chromanyl] ester; KBio1_001317; 989-51-5; AIDS-000674; (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate); KBio2_003364; Galloyl-L-epigallocatechol; SDCCGMLS-0066550.P001; (-)-Epigallocatechol gallate; ACon1_001054; Spectrum5_000102; Green tea extract; MEGxp0_001166; C09731; (-)-Epigallocatechin-3-o-gallate; Epigallocatechin 3-gallate; (-)-Epigallocatechin gallate; CCRIS 3729; Teavigo; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; Spectrum2_000168; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; (−)-cis-3,3′,4′,5,5′,7-Hexahydroxy-flavane-3-gallate; CHEBI:4806; (-)-epigallocatechin-3-gallate ; (-)-Epigallocatechin gallate (85% (-)-epigallocatechin gallate, 10% (-)-epigallocatechin, 5% (-)- epicatechin gallate); Catechin deriv.; SMR000449288; SPECTRUM210239; E4143_SIAL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; Spectrum_000316; (-)-EGCG; KBio3_001128; BSPBio_001628; Epigallocatechol, 3-gallate, (-)-; Epigallocatechin-3-gallate; E4268_SIAL; epigallocatechin gallate ; epigallocatechin-3-gallate; (-)epigallocatechin-3-gallate ; EGCG; 989E515; [5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 2,3,4-trihydroxybenzoate; HMS2051K21; CS-1258; AC1L22IG; AK165605; Green tea polyphenols, Anagen; (-)-Epigallocatechin-3-O-gallate, United States Pharmacopeia (USP) Reference Standard; AKOS015918182; CAS-989-51-5; Epigallocatechin gallate, primary pharmaceutical reference standard; W-5069; (-)-cis-3,3',4',5,5',7-Hexahydroxy-flavane-3-gallate; (-)-Epigallocatechin gallate, analytical standard; Q-100914; DSSTox_RID_78830; AN-15867; DSSTox_GSID_29889; (-)-Epigallocatechol gallate; FT-0604392; NCGC00164319-04; Green tea extract; MEGxp0_001166; (-)-Epigallocatechin-3-o-gallate; Epigallocatechin 3-gallate; N1874; CHEBI:4806; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; BG00814299; HMS3649E08; D0E9DB; Epigallocatechol, 3-gallate, (-)-; (-)-EpigallocatechinGallateHydrate; Epigallocatechin-3-gallate; AB0014381; BQM438CTEL; NC00078; ST51055716; Epigallocatechin gallate, Pharmaceutical Secondary Standard; Certified Reference Material; SpecPlus_000277; Spectrum3_000244; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl-3,4,5-trihydroxybenzoate; MLS000758300; (-)-Epigallocatechin gallate (EGCG); CCG-38378; Gallic acid, 3-ester with epigallocatechol, (-)-; SR-01000946601-1; NCGC00164319-01; (-)-cis-3,4-Dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-1(2H)-benzopyran-3-yl Gallate; NCGC00164319-06; DSSTox_CID_567; MCULE-3341525983; Epigallocatechin monogallate, B; Tox21_303457; SAM001247031; 4awm; K791; 989-51-5; SR-01000946601; MFCD00075940; EGCG analogs; Galloyl-L-epigallocatechol; NCGC00164319-03; (-)-Epigallocatechin gallate, >=80% (HPLC), from green tea; Spectrum5_000102; CPD000449288; (-)-Epigallocatechin gallate; LMPK12030005; E0694; Teavigo; Epigallocatechin gallate analogs, Anagen; Epigallocatechin-3-monogallate; ACN-035233; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; Sunphenon; Epigallocatechin gallate(EGCG); s2250; PF-EGCg 90; 3,4-Dihydro-5,7-dihydroxy-2R-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3R-yl-3,4,5-trihydroxybenzoate; 3,4,5-Trihydroxybenzoic acid (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; MLS001424000; (-)-EGCG; ZINC3870412; KBio2_000796; EGCG cpd; KBioGR_002002; Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, (2R-cis)-; EGCG, Anagen; NCGC00257243-01; Tox21_201468; L-Epigallocatechin gallate; cid_65064; SPBio_000035; BG01747388; Epigallocatechin gallate; KBioSS_000796; Spectrum4_001541; (-)-epigallocatechin 3-gallate; DB12116; EPIGALOCATECHIN GALLATE; ANTIOXIDANT MODEL (TRAMP) -EPIGALLOCATECHIN GALLATE; KBio2_005932; I14-7747; D0U2BH; MCULE-7760530136; 2kdh; Epigallocatechin gallate, Anagen; AOB2839; SDCCGMLS-0066550.P001; 863-65-0; FR-109; ST097428; ACon1_001054; LS-2197; CCRIS 3729; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; Epigallocate; GTPL7002; BDBM50070942; C22H18O11; GTPs,Anagen; SCHEMBL35258; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; MolPort-001-741-358; DivK1c_006373; KB-206444; SR-01000759328; Teavigo;; EGCG; (-)-EPIGALLOCATECHIN GALLATE (GREEN TEA EXTRACT); HY-13653; (-)-Epigallocatechin gallate, >=95%; NCGC00259019-01; Tea catechin; DS-9030; SR-01000759328-6; SR-01000759328-5; KDH; AC1Q5X0Z; KBio1_001317; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxyb enzoate; (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate); NVP-XAA 723; KBio2_003364; EBD2138593; FT-0082796; NCGC00164319-02; C09731; (-)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; UNII-BQM438CTEL; DTXSID1029889; WMBWREPUVVBILR-WIYYLYMNSA-N; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate; (-)-Epigallocatehin gallate; Spectrum2_000168; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate; (-)-Epigallocatechin gallate (85% (-)-epigallocatechin gallate, 10% (-)-epigallocatechin, 5% (-)- epicatechin gallate); Catechin deriv.; SMR000449288; (-)-Epigallocatechin gallat; SPECTRUM210239; Epigallocic acid; Epigallocatcchin Gallate; KS-0000132O; BP-30205; CHEMBL297453; SC-47284; Spectrum_000316; 3oob; (-)-Epigallocatechin gallate, >=97.0% (HPLC); KBio3_001128; BSPBio_001628; epigallo-catechin gallate | C22H18O11 | 458.4g/mol | C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O |
| TCMBANKIN059337 | CHD;cholalic acid;cholicacid | 5beta-Cholanic acid, 3alpha,7alpha,12alpha-trihydroxy- (7CI); cholic acid; 3alpha,7alpha,12alpha-Trihydroxycholanic acid; 81-25-4 (FREE ACID); CHOLATE; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid; 3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-oic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanoic acid; (3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxycholan-24-oic acid; 3alpha,7alpha,12alpha-Trihydroxy-beta-cholanic acid; (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; Colalin; C9377_SIGMA; SMR000112165; 3.alpha.,7.alpha.,12.alpha.-Trihydroxy-5.beta.-cholanic acid; AIDS017669; 5.beta.-Cholan-24-oic acid, 3.alpha.,7.alpha.,12.alpha.-trihydroxy-; MLS001066422; Cholan-24-oic acid, 3,7,12-trihydroxy-, (3alpha,5beta,7alpha,12alpha)- (9CI); AIDS-017669; Cholic acid (8CI); Cholalic acid; Cholan-24-oic acid, 3,7,12-trihydroxy-, (3-alpha,5-beta,7-alpha,12-alpha)-; Cholsaeure; C1129_SIGMA; ST024722; Spectrum5_002005; 5beta-Cholanic acid-3alpha,7alpha,12alpha-triol 5beta-Cholic acid; Cholalin; 17beta-[1-Methyl-3-carboxypropyl]etiocholane-3alpha,7alpha,12alpha-triol; 73163-53-8 (NA SALT); NSC-6135; 81-25-4; 3-&alpha,7-&alpha,12-&alpha-trihydroxy-5-&beta-cholanate; (3.alpha.,5.beta.,7.alpha.,12.alpha.)-3,7,12-Trihydroxycholan-24-oic acid sodium salt; (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]valeric acid; NSC6135; CHEBI:16359; C00695; LMST04010001;cholic acid;cholic acid | C24H40O5 | 408.57;408.6 g/mol | CC(CCC(=O)O)C1CCC2C1(C(CC3C2C(CC4C3(CCC(C4)O)C)O)O)C |
| TCMBANKIN059452 | ethyl aldehyde | C2H4O | 44.05 g/mol | CC=O | |
| TCMBANKIN059715 | vitamin a | C20H30O | 286.5 g/mol | CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CCO)C)C | |
| TCMBANKIN060104 | paristerone | C27H44O7 | 480.6 g/mol | CC12CCC3C(=CC(=O)C4C3(CC(C(C4)O)O)C)C1(CCC2C(C)(C(CCC(C)(C)O)O)O)O | |
| TCMBANKIN060958 | oleic acid;cis-oleic acid;oleinic acid | C18H34O2 | 282.46 | CCCCCCCCC=CCCCCCCCC(=O)O | |
| TCMBANKIN061091 | stearic acid | CH3(CH2)16COOH | 284.5 g/mol | CCCCCCCCCCCCCCCCCC(=O)O |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
| TCMBANKDI000009 | Neoplasms | Abnormality of the nervous system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI000061 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | group | |
| TCMBANKDI000076 | Neoplasms | - | Neoplastic Process | group | |
| TCMBANKDI000088 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | group | |
| TCMBANKDI000891 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI001152 | Infections; Respiratory Tract Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI002294 | - | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI003248 | Nutritional and Metabolic Diseases; Endocrine System Diseases | Abnormality of metabolism/homeostasis; Abnormality of the endocrine system | Disease or Syndrome | disease | |
| TCMBANKDI003353 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI003879 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Male Urogenital Diseases; Endocrine System Diseases | Abnormality of the genitourinary system | Congenital Abnormality | disease | |
| TCMBANKDI004086 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease | |
| TCMBANKDI004145 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | group | |
| TCMBANKDI004208 | Neoplasms | Neoplasm; Abnormality of the breast | Neoplastic Process | disease | |
| TCMBANKDI004376 | Neoplasms; Nervous System Diseases | - | Neoplastic Process | group | |
| TCMBANKDI004489 | - | Abnormality of the ear | Congenital Abnormality | disease | |
| TCMBANKDI004983 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications | - | Neoplastic Process | disease | |
| TCMBANKDI005868 | - | Abnormality of the nervous system | Finding | phenotype | |
| TCMBANKDI006612 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications | Abnormality of the genitourinary system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI006900 | - | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI007091 | Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI007281 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Disease or Syndrome | disease | |
| TCMBANKDI007737 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI010048 | Infections; Respiratory Tract Diseases | Abnormality of the immune system; Abnormality of the respiratory system | Disease or Syndrome | disease | |
| TCMBANKDI010395 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI010896 | Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | group | |
| TCMBANKDI011173 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI011596 | Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI011743 | Neoplasms; Skin and Connective Tissue Diseases | Neoplasm; Abnormality of the breast | Neoplastic Process | group | |
| TCMBANKDI012776 | Stomatognathic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI012976 | Neoplasms; Stomatognathic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI013628 | Neoplasms; Skin and Connective Tissue Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI015238 | Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI015452 | Neoplasms; Endocrine System Diseases | Abnormality of the endocrine system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI015485 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI015941 | - | - | Sign or Symptom | phenotype | |
| TCMBANKDI016336 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI016840 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Eye Diseases | Abnormality of the eye | Congenital Abnormality | disease | |
| TCMBANKDI016890 | Digestive System Diseases; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI017024 | Neoplasms; Respiratory Tract Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI017642 | Neoplasms | Abnormality of the integument; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI020602 | Male Urogenital Diseases | Abnormality of the genitourinary system | Disease or Syndrome | disease | |
| TCMBANKDI021278 | Eye Diseases | Abnormality of the eye | Disease or Syndrome | disease | |
| TCMBANKDI021622 | Mental Disorders | - | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI021796 | Male Urogenital Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI023140 | Neoplasms; Endocrine System Diseases | Abnormality of the endocrine system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI023751 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the musculature | Finding | phenotype | |
| TCMBANKDI024262 | - | - | Neoplastic Process | phenotype | |
| TCMBANKDI024535 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI024930 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI025368 | Infections; Nervous System Diseases; Mental Disorders | - | Disease or Syndrome | disease | |
| TCMBANKDI025420 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI026459 | Neoplasms; Respiratory Tract Diseases; Otorhinolaryngologic Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI027026 | Neoplasms; Skin and Connective Tissue Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI027040 | Immune System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI029783 | - | - | Diagnostic Procedure | phenotype | |
| TCMBANKDI030041 | Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI030078 | Infections; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI030540 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases | Abnormality of the genitourinary system; Neoplasm | Neoplastic Process | disease |
滇IICP备16009434号-1 |
Dai SX Lab